The FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and health-care systems to financial toxicities.

中文翻译：

---

NALIRIFOX 治疗转移性胰腺癌：希望还是炒作？

根据 NAPOLI 3 试验的结果，FDA 已批准纳米脂质体伊立替康、5-氟尿嘧啶、甲酰四氢叶酸和奥沙利铂 (NALIRIFOX) 用于治疗转移性胰腺腺癌患者，其中这种四药方案相对于双药方案改善了总生存期。在这里，我们讨论在 PRODIGE 4 试验测试 5-氟尿嘧啶、亚叶酸、伊立替康和奥沙利铂（改良版 FOLFIRINOX）的先前结果的背景下，NALIRIFOX 似乎并没有提高标准，而是使患者和医疗保健系统暴露于财务毒性。